Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 4
2021 3
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma.
Camus V, Viailly PJ, Drieux F, Veresezan EL, Sesques P, Haioun C, Durot E, Patey M, Rossi C, Martin L, Rainville V, Bohers E, Ruminy P, Penther D, Kaltenbach S, Bruneau J, Paillassa J, Tournilhac O, Willaume A, Antier C, Lazarovici J, Lévêque E, Decazes P, Becker S, Tonnelet D, Berriolo-Riedinger A, Gaulard P, Tilly H, Molina TJ, Traverse-Glehen A, Jardin F. Camus V, et al. Among authors: antier c. Blood Adv. 2023 Dec 12;7(23):7331-7345. doi: 10.1182/bloodadvances.2023011169. Blood Adv. 2023. PMID: 37862676 Free PMC article.
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.
Camus V, Rossi C, Sesques P, Lequesne J, Tonnelet D, Haioun C, Durot E, Willaume A, Gauthier M, Moles-Moreau MP, Antier C, Lazarovici J, Monjanel H, Bernard S, Tardy M, Besson C, Lebras L, Choquet S, Le Du K, Bonnet C, Bailly S, Damaj G, Laribi K, Maisonneuve H, Houot R, Chauchet A, Jardin F, Traverse-Glehen A, Decazes P, Becker S, Berriolo-Riedinger A, Tilly H. Camus V, et al. Among authors: antier c. Blood Adv. 2021 Oct 12;5(19):3862-3872. doi: 10.1182/bloodadvances.2021004778. Blood Adv. 2021. PMID: 34461634 Free PMC article.
Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience.
Laurent V, Fronteau C, Antier C, Dupuis P, Tessoulin B, Gastinne T, Mahé B, Blin N, Dubruille V, Lok A, Chevallier P, Guillaume T, Garnier A, Peterlin P, Le Bourgeois A, Vantyghem S, Tiab M, Godmer P, Sadot S, Loirat M, Trebouet A, Cormier N, Le Gouill S, Moreau P, Touzeau C. Laurent V, et al. Among authors: antier c. Bone Marrow Transplant. 2021 Feb;56(2):395-399. doi: 10.1038/s41409-020-01033-8. Epub 2020 Aug 14. Bone Marrow Transplant. 2021. PMID: 32796951
Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC.
Kaphan E, Bettega F, Forcade E, Labussière-Wallet H, Fegueux N, Robin M, Peffault De Latour R, Huynh A, Lapierre L, Berceanu A, Marcais A, Debureaux PE, Vanlangendonck N, Bulabois CE, Magro L, Daniel A, Galtier J, Lioure B, Chevallier P, Antier C, Loschi M, Guillerm G, Mear JB, Chantepie S, Cornillon J, Rey G, Poire X, Bazarbachi A, Rubio MT, Contentin N, Orvain C, Dulery R, Bay JO, Croizier C, Beguin Y, Charbonnier A, Skrzypczak C, Desmier D, Villate A, Carré M, Thiebaut-Bertrand A. Kaphan E, et al. Among authors: antier c. Transplant Cell Ther. 2023 Jun;29(6):362.e1-362.e12. doi: 10.1016/j.jtct.2023.02.020. Epub 2023 Feb 26. Transplant Cell Ther. 2023. PMID: 36849078 Free article.
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
Jullien M, Guillaume T, Le Bourgeois A, Peterlin P, Garnier A, Eveillard M, Le Bris Y, Bouzy S, Tessoulin B, Gastinne T, Dubruille V, Touzeau C, Mahé B, Blin N, Lok A, Vantyghem S, Sortais C, Antier C, Moreau P, Scotet E, Béné MC, Chevallier P. Jullien M, et al. Among authors: antier c. Am J Hematol. 2024 Mar;99(3):350-359. doi: 10.1002/ajh.27191. Epub 2024 Jan 2. Am J Hematol. 2024. PMID: 38165016 Clinical Trial.
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation.
Le Calvez B, Le Bris Y, Herbreteau G, Jamet B, Bossard C, Tessoulin B, Gastinne T, Mahé B, Dubruille V, Blin N, Antier C, Theisen O, Kraeber-Bodéré F, Le Gouill S, Béné MC, Moreau P, Touzeau C. Le Calvez B, et al. Among authors: antier c. EJHaem. 2020 Aug 6;1(1):318-322. doi: 10.1002/jha2.8. eCollection 2020 Jul. EJHaem. 2020. PMID: 35847743 Free PMC article.